Oncolytic Virotherapy as a Novel Treatment Platform for Cancer

2003 ◽  
pp. 89-105 ◽  
Author(s):  
D. Kirn
Keyword(s):  
Oncolytic Virotherapy ◽  
Novel Treatment

scholarly journals Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice

2021 ◽  
pp. 432-441
Author(s):  
Omeed Moaven ◽  
Christopher W. Mangieri ◽  
John A. Stauffer ◽  
Panos Z. Anastasiadis ◽  
Mitesh J. Borad
Keyword(s):  
Clinical Practice ◽  
Treatment Options ◽  
Cytolytic Activity ◽  
Oncolytic Viruses ◽  
Treatment Modalities ◽  
Oncolytic Virotherapy ◽  
Novel Treatment ◽  
Genetically Engineer ◽  
Essential Components

Selective oncotropism and cytolytic activity against tumors have made certain viruses subject to investigation as novel treatment modalities. However, monotherapy with oncolytic viruses (OVs) has shown limited success and modest clinical benefit. The capacity to genetically engineer OVs makes them a desirable platform to design complementary treatment modalities to overcome the existing treatment options' shortcomings. In recent years, our knowledge of interactions of the tumors with the immune system has expanded profoundly. There is a growing body of literature supporting immunomodulatory roles for OVs. The concept of bioengineering these platforms to induce the desired immune response and complement the current immunotherapeutic modalities to make immune-resistant tumors responsive to immunotherapy is under investigation in preclinical and early clinical trials. This review provides an overview of attempts to optimize oncolytic virotherapy as essential components of the multimodality anticancer therapeutic approach and discusses the challenges in translation to clinical practice.

Botulinum toxin as a novel treatment for self-mutilation in Lesch–Nyhan syndrome

2005 ◽  
Vol 47 (09) ◽  
pp. 636 ◽  
Author(s):  
Edward Dabrowski ◽  
Sarah A Smathers ◽  
Curt S Ralstrom ◽  
Michael A Nigro ◽  
Jimmie P Leleszi
Keyword(s):  
Botulinum Toxin ◽  
Novel Treatment ◽  
Self Mutilation

The proteasome inhibitor Bortezomib and oncolytic virotherapy act synergistically in hepatocellular carcinoma

2008 ◽  
Vol 46 (09) ◽  
Author(s):  
B Boozari ◽  
T Wirth ◽  
N Woller ◽  
MP Manns ◽  
S Kubicka ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Proteasome Inhibitor ◽  
Oncolytic Virotherapy

Efficacy of HCC treatment with Proteasome Inhibitor Bortezomib is increased by Oncolytic Virotherapy mediated downregulation of Mcl-1 and Bip

2009 ◽  
Vol 47 (01) ◽  
Author(s):  
B Boozari ◽  
T Wirth ◽  
N Woller ◽  
MP Manns ◽  
S Kubicka ◽  
...  
Keyword(s):  
Proteasome Inhibitor ◽  
Oncolytic Virotherapy

Novel treatment for walled-off necrosis (WON)

2009 ◽  
Vol 47 (05) ◽  
Author(s):  
Á Pap ◽  
M Burai ◽  
Á Tarpay
Keyword(s):  
Novel Treatment ◽  
Walled Off Necrosis

Targeting placental trophoblast leukemia inhibitory factor with a unique inhibitor: a novel treatment strategy for ectopic pregnancy

2014 ◽  
Author(s):  
Amy Winship ◽  
Tara Trishnan ◽  
Ellen Menkhorst ◽  
Andrew W Horne ◽  
Jeremy K Brown ◽  
...  
Keyword(s):  
Ectopic Pregnancy ◽  
Treatment Strategy ◽  
Leukemia Inhibitory Factor ◽  
Inhibitory Factor ◽  
Novel Treatment
Sign in / Sign up

Export Citation Format

Share Document